John C. Villforth
Plus aucun poste en cours
Profil
John C.
Villforth worked as a Director at Vasogen, Inc. from 2001 to 2009.
He also worked as a Director at Kaplan EduNeering, Inc. and as an Executive Director at The Food & Drug Law Institute.
Additionally, he worked as a Director at the Center for Devices & Radiological Health.
Anciens postes connus de John C. Villforth
| Sociétés | Poste | Fin |
|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Directeur/Membre du Conseil | 23/10/2009 |
| Center for Devices & Radiological Health | Directeur/Membre du Conseil | - |
The Food & Drug Law Institute
 The Food & Drug Law Institute Miscellaneous Commercial ServicesCommercial Services The Food & Drug Law Institute is a nonprofit membership organization that provides education, training, publications, and professional engagement opportunities in the field of food and drug law. The non-profit company is based in Washington. The American company offers a platform for stakeholders to inform innovative public policy, law, and regulation. Christine M. Simmon has been the CEO of the company since 2022. | Directeur/Membre du Conseil | - |
Kaplan EduNeering, Inc.
 Kaplan EduNeering, Inc. Miscellaneous Commercial ServicesCommercial Services Kaplan EduNeering, Inc. engages in the provision of online training services. The company was founded in 1980 and is headquartered in Princeton, NJ. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Kaplan EduNeering, Inc.
Kaplan EduNeering, Inc. Miscellaneous Commercial ServicesCommercial Services Kaplan EduNeering, Inc. engages in the provision of online training services. The company was founded in 1980 and is headquartered in Princeton, NJ. | Commercial Services |
The Food & Drug Law Institute
The Food & Drug Law Institute Miscellaneous Commercial ServicesCommercial Services The Food & Drug Law Institute is a nonprofit membership organization that provides education, training, publications, and professional engagement opportunities in the field of food and drug law. The non-profit company is based in Washington. The American company offers a platform for stakeholders to inform innovative public policy, law, and regulation. Christine M. Simmon has been the CEO of the company since 2022. | Commercial Services |
| Center for Devices & Radiological Health | Government |